Related by context. All words. (Click for frequent words.) 80 cancers 73 malignancy 72 lymphomas 71 neoplasms 70 epithelial tumors 70 bladder cancers 69 prostate cancers 69 tumors 69 metastases 69 metastatic disease 68 brain metastases 68 malignant tumors 68 sarcomas 68 gastrointestinal cancers 68 solid tumors 67 renal cell carcinoma 67 neuroendocrine tumors 67 metastatic cancer 67 endometrial cancers 67 carcinomas 66 GISTs 66 ovarian cancers 66 carcinoma 66 serous ovarian cancer 66 cell lymphomas 66 pancreatic cancers 65 nonmelanoma skin cancers 65 metastatic 65 osteosarcomas 65 esophageal cancers 65 neoplasia 65 colorectal cancers 65 lung cancers 65 neoplasm 65 precursor lesions 65 gastric cancers 65 colon cancers 65 NSCLC 65 squamous cell carcinomas 65 lung tumors 65 pancreatic adenocarcinoma 65 oropharyngeal cancer 65 colorectal cancer CRC 65 ovarian tumors 65 melanomas 65 MGUS 65 colorectal cancer 64 basal cell carcinoma BCC 64 soft tissue sarcomas 64 carcinoid tumors 64 metastatic cancers 64 glioblastoma 64 breast cancers 64 hepatocellular carcinoma 64 meningiomas 64 epithelial cancers 64 bone metastasis 64 adenocarcinomas 64 prostate cancer CaP 64 leukemias 64 distant metastasis 63 colorectal tumors 63 prostate pancreatic 63 hematologic malignancies 63 premalignant 63 skeletal metastases 63 gastric cancer 63 basal cell carcinomas 63 neuroendocrine cancers 63 liver metastases 63 differentiated thyroid 63 pulmonary metastases 63 hematologic disorders 63 premalignant lesions 63 carcinoid 63 papillary 63 testicular cancers 63 leukaemias 63 mesotheliomas 63 malignant neoplasms 62 ovarian lung 62 squamous cell cancers 62 HNSCC 62 malignant growths 62 ependymomas 62 neuroblastomas 62 thyroid cancers 62 tumor recurrence 62 follicular lymphoma 62 metastasis 62 histologies 62 myeloproliferative diseases 62 medulloblastomas 62 prostate adenocarcinoma 62 metastatic lesions 62 renal tumors 62 MALT lymphoma 62 neoplastic lesions 62 distant metastases 62 melanoma 62 hepatocellular carcinoma HCC 61 adenocarcinoma 61 grade gliomas 61 skin cancers 61 metastatic tumors 61 breast carcinoma 61 metastatic colorectal cancer 61 pheochromocytoma 61 gliomas 61 bone metastases 61 medullary thyroid cancer 61 squamous cell carcinoma 61 sarcoma 61 hamartomas 61 renal cell carcinomas 61 adenomatous polyps 61 invasive ductal 61 hepatocellular cancer 61 nonsmall cell lung cancer 61 advanced adenomas 61 prostate cancer PCa 61 gastrointestinal stromal tumors 61 carcinoid tumor 61 tyrosine kinase inhibitors 61 EGFR inhibitors 60 colorectal polyps 60 squamous cell carcinoma SCC 60 ovarian carcinoma 60 metastatic RCC 60 prostate breast 60 anti angiogenic therapy 60 cell carcinoma 60 locoregional recurrence 60 malignant lesions 60 PCa 60 lymphoproliferative disorders 60 lobular carcinoma 60 tumor progression 60 leiomyosarcoma 60 cervical lesions 60 endometrial cancer 60 neoplastic 60 nasopharyngeal carcinoma 60 pituitary adenomas 60 Candida infection 60 squamous cell 60 gastric adenocarcinoma 60 adenomas 60 neoplasias 60 malignant pleural mesothelioma 60 colorectal carcinoma 60 nonmelanoma skin cancer 60 basal cell 60 leukemia ALL 60 endometrial hyperplasia 60 essential thrombocythemia 60 grade cervical intraepithelial 60 micrometastases 60 hematological malignancies 60 histological subtypes 60 BRCA mutations 60 myelofibrosis polycythemia vera 60 cholangiocarcinoma 60 breast carcinomas 60 MMP inhibitors 60 gynecological malignancies 60 leiomyomas 60 endometrial carcinoma 60 invasive carcinoma 60 tumor 60 paragangliomas 60 Hepatocellular Carcinoma HCC 60 HbF 60 metastatic prostate cancer 60 acute leukemias 60 squamous 60 CaP 60 medulloblastoma 60 CMV infection 60 toxicities 60 lymph node metastases 60 non Hodgkin lymphomas 60 hyperplastic 59 lung carcinomas 59 chronic GVHD 59 grade serous ovarian 59 thyroid nodules 59 EGFR mutations 59 cervical carcinoma 59 glioblastomas 59 bowel cancers 59 mycosis fungoides 59 lung nodules 59 lymphoma subtypes 59 ovarian cancer 59 metastatic melanomas 59 colorectal 59 ALK mutations 59 lung adenocarcinoma 59 breast tumors 59 colorectal lung 59 pancreatic carcinoma 59 metastatic melanoma 59 HER2 positive cancers 59 precancers 59 malignant melanoma 59 superficial bladder cancer 59 recurrent NSCLC 59 atypical hyperplasia 59 malignant lymphomas 59 systemic lupus erythematosus SLE 59 ALCL 59 indolent NHL 59 myelodysplastic syndrome MDS 59 testicular germ cell 59 pre cancerous lesions 59 renal carcinoma 59 hematological cancers 59 pancreatic lung 59 gynecological cancers 59 cardiotoxicity 59 ovarian breast 59 nonmetastatic 59 thromboembolic events 59 Non Hodgkin lymphoma 59 Kaposi sarcoma 59 myeloproliferative neoplasms 59 uveal melanoma 59 cutaneous melanoma 59 gastric carcinoma 59 imatinib Gleevec 59 seminoma 59 metastatic renal cell carcinoma 59 carcinoids 59 disease progression 59 tumor metastases 59 uterine cancers 59 hematological diseases 59 Toxicities 59 castration resistant prostate cancer 59 gynecologic cancers 59 molecular abnormalities 59 squamous cell cancer 59 neuroendocrine carcinoma 59 malignant neoplasm 59 CMV disease 59 lesions 59 fallopian tube carcinoma 59 prostate cancer CRPC 59 astrocytomas 59 colorectal gastric 59 ductal cancer 59 PCNSL 58 lymphoid 58 mucinous 58 Carcinoma 58 operable breast cancer 58 sarcomatoid 58 intestinal metaplasia 58 breast endometrial 58 Chronic lymphocytic leukemia 58 Sjögren syndrome 58 metastatic kidney 58 Cholangiocarcinoma 58 anal cancers 58 etiologies 58 histologic subtype 58 H. pylori infection 58 axillary lymph nodes 58 gynecologic malignancy 58 breast ovarian 58 pancreatic NET 58 lymphatic tissue 58 Metastases 58 SCCHN 58 Gastric cancer 58 Gliomas 58 congenital anomalies 58 adjuvant therapy 58 colorectal adenomas 58 histological subtype 58 mucosal lesions 58 HCV infection 58 mutated KRAS gene 58 untreated celiac disease 58 hematologic 58 seminomas 58 urothelial carcinoma 58 precancerous lesions 58 benign growths 58 precancerous cervical lesions 58 schwannomas 58 HER2 positive breast cancer 58 invasive breast cancer 58 leukemia AML 58 MYCN amplification 58 Synovial sarcoma 58 Metastatic breast cancer 58 multiple myeloma 58 basal cell cancers 58 rectal cancers 58 myeloproliferative disorders 58 hyperplasia 58 hematologic cancers 58 cell carcinomas 58 CYT# potent vascular disrupting 58 hormonal therapies 58 BRCA1 mutations 58 metastatic colorectal 58 systemic scleroderma 58 anti angiogenic drugs 58 extracranial 58 node metastases 58 advanced adenoma 58 atherosclerotic disease 58 lobular cancer 58 epithelial ovarian cancer 58 FGFR2 58 pleural mesothelioma 58 oesophageal 58 Glioblastoma 58 thrombotic events 58 lipomas 58 neuroblastoma tumors 58 liposarcoma 58 cancer mCRC 58 leiomyoma 58 respiratory viral infections 58 Squamous cell 58 malignant gliomas 58 Basal cell 58 gastrointestinal stromal tumor 58 hematological disorders 58 cell malignancies 58 nonmelanoma 58 epithelial ovarian 58 chemotherapeutic agents 57 TTR amyloidosis 57 Acute lymphoblastic leukemia 57 parathyroid 57 ccRCC 57 molecular subtypes 57 Recurrences 57 Metastatic 57 chlamydial infection 57 resistant ovarian cancer 57 endometrial 57 angiosarcoma 57 Adjuvant chemotherapy 57 lung pancreatic 57 tumor subtypes 57 Endometrial cancer 57 malignant transformation 57 ductal breast cancer 57 IGF 1R 57 lung prostate 57 squamous cell lung cancer 57 relapsed ovarian cancer 57 basal cell nevus syndrome 57 metastatic bladder 57 MEK inhibitors 57 glioblastoma multiforme GBM 57 metachronous 57 lymphoma 57 p# mutations 57 pancreatic ovarian 57 adenoma 57 anaplastic 57 lung adenocarcinomas 57 ADPKD 57 HER2 positive metastatic breast 57 mTOR inhibitors 57 transitional cell carcinoma 57 pre malignant lesions 57 dasatinib 57 glioma 57 tumor malignancies 57 acute myelogenous leukemia AML 57 cutaneous squamous cell carcinoma 57 fibrosis 57 tumoral 57 heavily pretreated 57 hypercalcemia 57 cell lung cancer 57 leukemias lymphomas 57 ependymoma 57 chronic lymphocytic leukemia CLL 57 Papillary 57 follicular thyroid cancer 57 K ras mutations 57 pathologic 57 non squamous NSCLC 57 Basal cell carcinoma 57 thromboembolic disease 57 NF kB pathway 57 benign neoplasms 57 myeloma cells 57 HRPC 57 HCV infections 57 trans retinoic acid 57 genetic aberrations 57 liver metastasis 57 Brain metastases 57 xenograft models 57 grade glioma 57 anthracyclines 57 intracranial tumors 57 lobular carcinomas 57 recurrent glioblastoma multiforme GBM 57 LHRH receptor positive 57 Hurthle cell 57 CLL 57 prostate carcinoma 57 liver fibrosis 57 metastatic colon cancer 57 oncogenic HPV types 57 smoldering myeloma 57 breast pancreatic 57 cancer 57 GIST tumors 57 vestibular schwannomas 57 brain tumors 57 taxane therapy 57 chemotherapeutic regimens 57 lobular breast cancer 57 Sezary syndrome 57 atypia 57 prognostic markers 57 Pancreatic neuroendocrine tumors 57 PNET 57 BRCA deficient 57 germline mutations 57 esophageal squamous cell carcinoma 57 haematopoietic 57 candidemia 57 HPV infection 57 cervical dysplasia 57 cholelithiasis 57 postmenopausal breast cancer 57 diabetic nephropathy 57 prostate lung 57 GIST 57 atherosclerotic lesions 57 idiopathic myelofibrosis 57 testicular tumors 57 hereditary breast cancer 57 metastatic neuroendocrine tumors 57 gastrointestinal stromal tumors GISTs 57 urothelial bladder cancer 57 cystic lesions 57 lymphoid tumors 57 metastatic lung cancer 57 lung cancer 57 T1DM 57 peritoneal carcinomatosis 57 lung metastasis 57 curable cancers 56 proliferative diabetic retinopathy 56 Acute myeloid leukemia 56 pCR 56 cervical intraepithelial neoplasia 56 benign tumors 56 metastatic malignant melanoma 56 carcinoma HNSCC 56 colorectal neoplasms 56 lung metastases 56 myelofibrosis 56 cranial irradiation 56 cervical lymph nodes 56 esophageal adenocarcinoma 56 chromosomal rearrangement 56 incidentalomas 56 GBM tumors 56 sporadic ALS 56 Cancers 56 pegylated liposomal doxorubicin 56 cancerous tumors 56 pancreatic prostate 56 pleomorphic 56 chondrosarcoma 56 chronic periodontitis 56 contralateral breast 56 platinum refractory 56 haematological malignancies 56 Malignant tumors 56 staphylococcal infections 56 acute GvHD 56 prostate cancer 56 Medullary thyroid cancer 56 biochemical recurrence 56 de ath 56 endocrine tumors 56 Lymphomas 56 synovial sarcoma 56 lupus nephritis 56 chromosomal abnormalities 56 colon tumors 56 TNF blocker therapy 56 nodal metastasis 56 Epstein Barr virus EBV 56 colorectal adenoma 56 prognostic variables 56 hepatocellular carcinomas 56 ansamycin 56 paraganglioma 56 chemoradiation 56 cisplatin resistant 56 pancreatic tumors 56 adenomatous 56 malignant lymphoma 56 JAK inhibitors 56 fibroadenomas 56 Carcinoid tumors 56 pulmonary metastasis 56 pre cancerous polyps 56 castrate resistant prostate cancer 56 papillary RCC 56 VUR 56 carcinoid cancer 56 breast cancer subtypes 56 mammary cancers 56 heavily pretreated patients 56 alveolar rhabdomyosarcoma 56 basal cell skin 56 hematopoietic cancers 56 prognostic indicator 56 Follicular lymphoma 56 rectal cancer 56 pancreatic colon 56 basal cell carcinoma 56 unknown etiology 56 thymic carcinoma 56 EGFR mutation 56 PI3K inhibitors 56 cytoreduction 56 Glioblastoma multiforme GBM 56 nonproliferative 56 histologic 56 tumor xenograft models 56 Barrett esophagus BE 56 chemotherapy regimens 56 Bladder cancer 56 colorectal breast 56 NF1 56 castrate resistant 56 Myelodysplastic syndromes MDS 56 panobinostat 56 androgen deprivation 56 hemorrhagic complications 56 histologic subtypes 56 anemias 56 gastrointestinal stromal tumor GIST 56 JAK mutations 56 lymphadenopathy 56 prognostic factors 56 prognostic marker 56 HGPIN 56 recurrent ovarian cancer 56 therapeutic regimens 56 breast lesions 56 PARP inhibition 56 astrocytoma 56 androgen receptor AR 56 colorectal polyp 56 prostate carcinomas 56 nodal metastases 56 indolent lymphomas 56 calculi 56 Alessandro Riva 56 malignant prostate 56 small lymphocytic lymphoma 56 urothelial cancer 56 Gorlin syndrome 56 Osteosarcoma 56 EGFR pathway 56 Sarcomas 56 HBeAg negative 56 proximal colon 56 standard chemotherapy regimens 56 lung cancer NSCLC 56 brain tumor glioblastoma multiforme 56 penile cancers 56 Squamous cell carcinomas 56 somatic mutations 56 nasopharyngeal cancer 56 familial adenomatous polyposis 56 mycophenolate mofetil 56 c MYC 56 ocular disorders 56 systemic lupus erythematosus 56 docetaxel Taxotere ® 55 HDACi 55 malignant pancreatic 55 neurologic complications 55 cytoreductive surgery 55 adjuvant therapies 55 pediatric acute lymphoblastic 55 axillary node dissection 55 haematological cancers 55 familial ALS 55 LHRH analogues 55 colorectal liver metastases 55 Surgical resection 55 Renal cell carcinoma 55 chemo resistant 55 Non Hodgkin lymphomas 55 NAFLD 55 contralateral breast cancer 55 keloids 55 solar keratosis 55 BCR ABL mutations 55 lung lesions 55 colorectal carcinomas 55 APOL1 55 MAPK pathway 55 Rectal cancer 55 thalidomide Thalomid 55 chemoradiotherapy 55 angiogenesis inhibition 55 Glioblastomas 55 papillary thyroid cancer 55 Metastatic melanoma 55 abnormalities 55 meningioma 55 lung colorectal 55 cancerdefine 55 lymph node metastasis 55 unresectable 55 Chronic Lymphocytic Leukemia CLL 55 aerodigestive tract 55 autoimmune diseases 55 stage IIIA 55 Thyroid nodules 55 cisplatin chemotherapy 55 AA amyloidosis 55 peritoneal cancer 55 investigational therapies 55 situ CIS 55 recurrences 55 Gleevec resistant 55 imatinib resistance 55 Wilms tumors 55 kidney urologic 55 papillary renal cell carcinoma 55 sCJD 55 kinase inhibition 55 fibrotic disease 55 severe hypersensitivity reactions 55 cytotoxic agents 55 pericardial effusion 55 aneuploid cells 55 epithelioid 55 pituitary tumors 55 solid organ transplantation 55 myelosuppression 55 thromboembolism 55 pleural effusions 55 metastatic breast cancer 55 ovarian pancreatic 55 metastatic renal 55 bronchogenic carcinoma 55 lymph node enlargement 55 immunohistochemical staining 55 gastrointestinal perforation 55 HER2 positive 55 myelomas 55 malignant fibrous histiocytoma 55 HNPCC 55 PNH patients 55 multiple myeloma MM 55 ascites 55 herpesviruses 55 pre cancerous growths 55 gemcitabine Gemzar 55 posaconazole 55 chronic HBV infection 55 TEAEs 55 prostate tumors 55 relapsing remitting 55 HPV infections 55 arterial calcification 55 vertebral fracture 55 thrombophilia 55 macrovascular events 55 GBMs 55 pancreatic neuroendocrine tumors 55 teratoma 55 thyrotoxicosis 55 metastatic prostate 55 Hodgkin lymphoma HL 55 myeloid leukemia 55 prognostic significance 55 invasive candidiasis 55 FLT3 55 intra abdominal abscess 55 activating mutations 55 oligodendrogliomas 55 solar keratoses 55 Wilms tumor 55 thymoma 55 recurrent miscarriage 55 preclinical xenograft models 55 pulmonary emboli 55 carcinoma HCC 55 acute myeloid leukemia AML 55 gene rearrangements 55 non metastatic osteosarcoma 55 malignant polyps 55 myopathies 55 Anaplastic 55 metastatic gastric 55 Li Fraumeni Syndrome 55 neoadjuvant therapy 55 KRAS wild 55 WT1 55 gynecologic cancer 55 adenomatous polyp 55 breast cancer metastasis 55 thrombotic complications 55 intravesical therapy 55 cytotoxic chemotherapy 55 lymphocytosis 55 cetuximab Erbitux 55 basal cells 55 pilocytic astrocytomas 55 EBV infection 55 urolithiasis 55 coagulation disorders 55 lymphoid tissue 55 glioblastoma tumors 55 allogeneic HSCT 55 nasopharyngeal carcinoma NPC 55 myelodysplastic syndromes MDS 55 venous blood clots 55 anti angiogenic agents 55 lobular 55 AEG# 55 fallopian tube cancers 55 tumors GIST 55 MGd 55 lymphadenectomy 55 tumor histology 55 hematologic toxicity 55 gastric pancreatic 55 BRAF mutation 55 locoregional 55 cell lymphoma ALCL 55 recurrent glioblastoma multiforme 55 completely resected 55 cirrhosis liver failure 55 mitochondrial toxicity 55 node metastasis 55 VEGF inhibitors 55 Uterine fibroids 55 osteosarcoma 55 inflammatory bowel disease 55 neurological manifestations 55 DIPG 55 Colorectal cancer CRC 55 GvHD 55 BRAF mutations 55 motor neuron degeneration 55 advanced NSCLC 55 ruptured aneurysms 55 Barrett esophagus 55 hematopoietic malignancies 55 PARP inhibitors 55 varicella infection 55 macrovascular complications 55 hemangiomas 55 benign polyps 55 BRCA mutation carriers 55 stage IIIB 55 endostatin 55 prostate carcinogenesis 55 congenital malformations 55 recurrent glioblastoma 55 carcinogenesis 55 ductal carcinomas 55 metastatic ovarian cancer 55 systemic fungal infections 55 myocardial infarctions 54 intestinal polyps 54 Melanomas 54 nonalcoholic steatohepatitis NASH 54 Tumours 54 adrenocortical cancer 54 thyroid tumors 54 apoptotic pathway 54 colorectum 54 colon pancreatic 54 invasive ductal carcinoma 54 neurofibromas 54 Pseudomonas aeruginosa infections 54 familial pancreatic cancer 54 scleroderma 54 nephrogenic 54 colorectal adenocarcinoma 54 DLBCL 54 zalutumumab 54 HER2 overexpression 54 laryngeal cancer 54 genetic abnormalities 54 curability 54 Helicobacter pylori infection 54 malignant melanomas 54 histologically 54 carcinomatosis 54 hormone refractory prostate cancer 54 noncancerous cells 54 S. aureus infections 54 microvascular complications 54 oncogenesis 54 polycythemia vera PV 54 nodular melanoma 54 pulmonary nodules 54 mammary tumors 54 molecularly targeted 54 hyperplastic polyps 54 malignant pheochromocytoma 54 epithelial tissues 54 hyperoxaluria 54 secondary hyperparathyroidism 54 situ LCIS 54 monoclonal gammopathy 54 metaplasia 54 CIN3 54 primary hyperparathyroidism 54 unresectable tumors 54 cervical breast 54 acute GVHD 54 axitinib 54 Basal Cell 54 chronic eosinophilic leukemia 54 hyperbilirubinemia 54 carotid plaques 54 cediranib 54 thromboembolic 54 leukoencephalopathy 54 neuropathies 54 bevacizumab Avastin ® 54 gastrointestinal malignancies 54 mRCC 54 allograft rejection 54 uterine ovarian 54 Stomach cancer 54 grade dysplasia 54 infective endocarditis 54 melanoma tumors 54 colorectal pancreatic 54 Radical prostatectomy 54 neovascular AMD 54 lichen planus 54 depsipeptide 54 gastroesophageal junction 54 myeloproliferative disorder 54 pain syndromes 54 hematologic malignancy 54 muscular dystrophies 54 endometrioid 54 endometrial ovarian 54 pancytopenia 54 diagnostic biomarker 54 hamartoma 54 TTR gene 54 alkylating agents 54 recurrent metastatic 54 invasive aspergillosis 54 B CLL 54 pre cancerous 54 esophageal tumors 54 atherothrombosis 54 tumor suppressor genes 54 juvenile idiopathic arthritis 54 GnRH agonists 54 lipid abnormalities 54 esophageal carcinoma 54 axillary dissection 54 melanoma skin 54 KRAS mutations occur 54 dysglycemia 54 hepatic metastases 54 BRCA2 mutations 54 androgenetic alopecia 54 Bone metastases 54 ductal adenocarcinoma 54 lymph node involvement 54 cytogenetic abnormalities 54 situ DCIS 54 C. trachomatis 54 noncancerous tumors 54 amenorrhoea 54 proliferative disorders 54 Hashimoto thyroiditis 54 receptor tyrosine kinase inhibitor 54 pheochromocytomas 54 proto oncogene 54 atrophic gastritis 54 pertuzumab 54 papillomas 54 herpes zoster shingles 54 TRAIL R1 54 desmoplastic 54 nucleoside analogues 54 oncoproteins 54 germline mutation 54 lymph node removal 54 oesophageal adenocarcinoma 54 chlamydial infections 54 choriocarcinoma 54 hypermethylation 54 IL 1ß 54 carotid stenosis 54 neoplastic diseases 54 CD# mAb 54 chromosomal aberrations 54 pathologic fractures 54 tumor necrosis 54 cytogenetic responses 54 BRAF gene 54 thyroid carcinoma 54 Basal cell carcinomas 54 PTEN mutations 54 uveitis 54 parathyroid carcinoma 54 liver cancer 54 TNFa 54 childhood leukemias 54 p#INK#a 54 geographic atrophy 54 Zolinza 54 TNF antagonist 54 hematological 54 Renal Cell Carcinoma RCC 54 Glucocorticoids 54 BRCA2 mutation carriers 54 Testicular cancer 54 ARVD 54 pancreatic islet cell 54 tumor xenografts 54 biliary strictures 54 gastric atrophy 54 familial amyloidotic polyneuropathy FAP 54 lymphocytic 54 transplantation HCT 54 rebleeding 54 EGFR 54 cervical cancers 54 acute coronary syndromes ACS 54 varices 54 Aspergillus infections 54 osteochondromas 54 tumor lysis syndrome 54 BRCA1 mutation carriers 54 imatinib resistant 54 Aurora kinase 54 invasive fungal infections 54 malformations 54 pelvic malignancies 54 intravenous bisphosphonates 54 colon pancreas 54 sorafenib Nexavar 54 squamous carcinoma 54 non Hodgkin lymphoma 54 noncardiac 54 hydronephrosis 54 invasive fungal infection 54 organ transplant rejection 54 demyelinating diseases 54 microvascular disease 54 stratifying patients 54 E#F# 54 pT2 54 cerebral infarction 54 KRAS mutations 54 EGFr 54 xenograft tumors 54 etiologic 54 Actinic Keratosis 54 adjuvant radiation 54 haematological 54 thyroid carcinomas 54 bladder tumors 54 gefitinib Iressa 54 rheumatic diseases 54 BCCs 54 cerebral vasospasm 54 hypereosinophilic syndrome 54 GVHD 54 hypertrophic scars 54 hormone receptor positive 54 NKT cells 54 invasive carcinomas 54 lymphoid cells 54 immunocompetent 54 Hematologic 54 biliary tract cancer 54 papillary thyroid carcinoma 54 inherited mutations